CD8A and neoplasm: Surprisingly, the percentages of CD8+ T cells showed no significant differences among control, anti-PD-1, and DNase I-treated group (Figure 3A,B); however, the percentages of CD8+ T cells increased in the tumor following combination treatment with anti-PD-1 mAB and DNase I (Figure 3A,B).